Hypertension Pharmacogenomics

Handbook of Pharmacogenomics and Stratified Medicine

Volumn , Issue , 2014, Pages 747-778

  Gong, Yan ^a   McDonough, Caitrin W ^a   Padmanabhan, Sandosh ^b   Johnson, Julie A ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Antihypertensives; Beta blockers; Calcium channel blockers; Diuretics; Genetic polymorphisms; High blood pressure; Hypertension; Pharmacogenomics

Indexed keywords

EID: 84942082784     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386882-4.00032-3     Document Type: Chapter

References (202)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Collaboration PS Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
2. Evans JG, Rose G Hypertension. Br Med Bull 1971, 27(1):37-42.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217-223.
4. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012, 380(9859):2224-2260.
5. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A High-normal blood pressure progression to hypertension in the Framingham heart study. Hypertension 1991, 17(1):22-27.
6. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham heart study. Circulation 1997, 96(1):308-315.
7. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH Weight and blood pressure. Findings in hypertension screening of 1million Americans. JAMA 1978, 240(15):1607-1610.
8. Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH Salt and hypertension: is salt dietary reduction worth the effort?. Am J Med 2012, 125(5):433-439.
9. He FJ, MacGregor GA Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002, 16(11):761-770.
10. Kaminer B, Lutz WP Blood pressure in Bushmen of the Kalahari desert. Circulation 1960, 22:289-295.
11. Truswell AS, Kennelly BM, Hansen JD, Lee RB Blood pressures of Kung Bushmen in Northern Botswana. Am Heart J 1972, 84(1):5-12.
12. Poulter NR, Khaw KT, Hopwood BE, Mugambi M, Peart WS, Rose G, et al. The Kenyan Luo migration study: observations on the initiation of a rise in blood pressure. BMJ 1990, 300(6730):967-972.
13. Crews DE, Mancilha-Carvalho JJ Correlates of blood pressure in Yanomami Indians of Northwestern Brazil. Ethn Dis 1993, 3(4):362-371.
14. Carvalho JJ, Baruzzi RG, Howard PF, et al. Blood pressure in four remote populations in the INTERSALT study. Hypertension 1989, 14(3):238-246.
15. Laville M, Lengani A, Sermé D, Fauvel JP, Ouandaogo BJ, Zech P Epidemiological profile of hypertensive disease and renal risk factors in black Africa. J Hypertens 1994, 12(7):839-843. [discussion 45].
16. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 2005, 81(2):341-354.
17. Neel JV Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?. Am J Hum Genet 1962, 14:353-362.
18. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988-1991. Hypertension 1995, 25(3):305-313.
19. Nakajima T, Wooding S, Sakagami T, Emi M, Tokunaga K, Tamiya G, et al. Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world. Am J Hum Genet 2004, 74(5):898-916.
20. Weder AB Evolution and hypertension. Hypertension 2007, 49(2):260-265.
21. Young JH, Chang YP, Kim JD, Chretien JP, Klag MJ, Levine MA, et al. Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet 2005, 1(6):e82.
22. Brunner HR, Gavras H Is the renin system necessary?. Am J Med 1980, 69(5):739-745.
23. Mongeau JG, Biron P, Sing CF The influence of genetics and household environment upon the variability of normal blood pressure: the montreal adoption survey. Clin Exp Hypertens A 1986, 8(4-5):653-660.
24. Harrap SB, Stebbing M, Hopper JL, Hoang HN, Giles GG Familial patterns of covariation for cardiovascular risk factors in adults: the Victorian family heart study. Am J Epidemiol 2000, 152(8):704-715.
25. Hunt SC, Williams RR, Barlow GK A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986, 39(10):809-821.
26. Bochud M, Bovet P, Elston RC, Paccaud F, Falconnet C, Maillard M, et al. High heritability of ambulatory blood pressure in families of East African descent. Hypertension 2005, 45(3):445-450.
27. Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, McNamara PM Blood pressure aggregation in families. Am J Epidemiol 1979, 110(3):304-312.
28. Hottenga JJ, Boomsma DI, Kupper N, Posthuma D, Snieder H, Willemsen G, et al. Heritability and stability of resting blood pressure. Twin Res Hum Genet 2005, 8(5):499-508.
29. Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma DI, de Geus EJ Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension 2005, 45(1):80-85.
30. Snieder H, Harshfield GA, Treiber FA Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension 2003, 41(6):1196-1201.
31. Fava C, Burri P, Almgren P, Groop L, Hulthén UL, Melander O, et al. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension 1995, 26(6 Pt 1):919-924.
32. Fava C, Burri P, Almgren P, Groop L, Hulthén UL, Melander O Heritability of ambulatory and office blood pressure phenotypes in Swedish families. J Hypertens 2004, 22(9):1717-1721.
33. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, et al. Genome-wide mapping of human loci for essential hypertension. Lancet 2003, 361(9375):2118-2123.
34. Kurtz TW, Morris RC Dietary chloride as a determinant of "sodium-dependent" hypertension. Science 1983, 222(4628):1139-1141.
35. Whitescarver SA, Ott CE, Jackson BA, Guthrie GP, Kotchen TA Salt-sensitive hypertension: contribution of chloride. Science 1984, 223(4643):1430-1432.
36. Lifton RP, Gharavi AG, Geller DS Molecular mechanisms of human hypertension. Cell 2001, 104(4):545-556.
37. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355(6357):262-265.
38. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, et al. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000, 37(11):831-835.
39. Cerame BI, New MI Hormonal hypertension in children: 11beta-hydroxylase deficiency and apparent mineralocorticoid excess. J Pediatr Endocrinol Metab 2000, 13(9):1537-1547.
40. New MI, Levine LS Hypertension of childhood with suppressed renin. Endocr Rev 1980, 1(4):421-430.
41. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293(5532):1107-1112.
42. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995, 11(1):76-82.
43. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994, 79(3):407-414.
44. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40(5):592-599.
45. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267(5198):679-681.
46. Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, Marian AJ, Entman ML, et al. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci USA 2005, 102(39):13789-13794.
47. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasmnan DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478(7367):103-109.
48. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009.
49. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009, 41(3):348-353.
50. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians. Nat Genet 2011, 43(6):531-538.
51. Zhu X, Young JH, Fox E, Keating BJ, Franceschini N, Kang S, et al. Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet 2011, 20(11):2285-2295.
52. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010, 6(10):e1001177.
53. Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009, 41(6):712-717.
54. Welander J, Söderkvist P, Gimm O Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011, 18(6):R253-R276.
55. van Hulsteijn LT, Dekkers OM, Hes FJ, Smit JW, Corssmit EP Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet 2012, 49(12):768-776.
56. Touyz RM Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005, 90(4):449-455.
57. Xiang M, Feng M, Muend S, Rao R A human Na+/H+ antiporter sharing evolutionary origins with bacterial NhaA may be a candidate gene for essential hypertension. Proc Natl Acad Sci USA 2007, 104(47):18677-18681.
58. Blaustein MP Physiological effects of endogenous ouabain: control of intracellular Ca2+ stores and cell responsiveness. Am J Physiol 1993, 264(6 Pt 1):C1367-C1387.
59. Iwamoto T, Kita S, Zhang J, Blaustein MP, Arai Y, Yoshida S, et al. Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle. Nat Med 2004, 10(11):1193-1199.
60. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American heart association. Circulation 2013, 127(1):e6-e245.
61. Neal B, MacMahon S, Chapman N Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356(9246):1955-1964. Collaboration BPLTT, Blood Pressure Lowering Treatment Trialists' Collaboration.
62. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
63. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33(13):1635-1701.
64. Liu LS Hypertension WGoCGftMo. Zhonghua Xin Xue Guan Bing Za Zhi 2011, 39(7):579-615. [2010 Chinese guidelines for the management of hypertension].
65. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009, 32(1):3-107.
66. Bramlage P, Böhm M, Volpe M, Khan BV, Paar WD, Tebbe U, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) 2010, 12(9):666-677.
67. (CDC) CfDCaP Vital signs: awareness and treatment of uncontrolled hypertension among adults-United States, 2003-2010. MMWR Morb Mortal Wkly Rep 2012, 61:703-709.
68. Bidiville J, Nussberger J, Waeber G, Porchet M, Waeber B, Brunner HR Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988, 11(2):166-173.
69. Freis ED, Materson BJ, Flamenbaum V Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med 1983, 74(6):1029-1041.
70. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of veterans affairs cooperative study group on antihypertensive agents. N Engl J Med 1993, 328(13):914-921.
71. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366(9489):895-906.
72. Furberg CD, Wright JT, Davis BR, Cutler JR, Alderman M, Black H, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288(23):2981-2997.
73. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290(21):2805-2816.
74. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the nordic diltiazem (NORDIL) study. Lancet 2000, 356(9227):359-365.
75. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J 2009, 157(3):442-449.
76. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002, 61(3):1047-1055.
77. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007, 20(3):311-318.
78. Filigheddu F, Argiolas G, Bulla E, Troffa C, Bulla P, Fadda S, et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics 2008, 9(10):1419-1427.
79. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010, 23(9):1014-1022.
80. Hiltunen TP, Kontula K Clinical and molecular approaches to individualize antihypertensive drug therapy. Ann Med 2012, 44(Suppl. 1):S23-S29.
81. Duprez DA Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006, 24(6):983-991.
82. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972, 52(5):633-652.
83. Laragh JH Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973, 55(3):261-274.
84. Laragh JH, Letcher RL, Pickering TG Renin profiling for diagnosis and treatment of hypertension. JAMA 1979, 241(2):151-156.
85. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of veterans affairs cooperative study group on antihypertensive agents. JAMA 1998, 280(13):1168-1172.
86. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens 2008, 21(1):61-66.
87. Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens 2008, 26(6):1250-1256.
88. Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens 2013, 26(8):957-964.
89. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003, 17(2):81-86.
90. Johnson JA, Gong Y, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, et al. Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clin Pharmacol Ther 2009, 86(5):533-539.
91. Fan X, Han Y, Sun K, Wang Y, Xin Y, Bai Y, et al. Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension. Ann Pharmacother 2008, 42(12):1772-1781.
92. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008, 52(2):359-365.
93. Messerli FH, Bangalore S Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med 2011, 124(10):896-899.
94. Duarte JD, Cooper-DeHoff RM Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010, 8(6):793-802.
95. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349(9062):1353-1357.
96. Glorioso N, Filigheddu F, Cusi D, Troffa C, Conti M, Natalizio M, et al. Alpha-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 2002, 39(2 Pt 2):357-362.
97. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999, 34(4 Pt 1):649-654.
98. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003, 41(3):398-403.
99. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003, 16(10):834-839.
100. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013, 62(2):391-397.
101. Matayoshi T, Kamide K, Takiuchi S, Yoshii M, Miwa Y, Takami Y, et al. The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res 2004, 27(11):821-833.
102. Schelleman H, Klungel OH, Witteman JC, Hofman A, van Duijn CM, de Boer A, et al. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. Eur J Hum Genet 2006, 14(7):860-866.
103. Schunkert H, Hense HW, Döring A, Riegger GA, Siffert W Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998, 32(3):510-513.
104. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001, 37(2 Part 2):739-743.
105. Schelleman H, Stricker BH, Verschuren WM, de Boer A, Kroon AA, de Leeuw PW, et al. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J 2006, 6(1):22-26.
106. Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, et al. Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension 2005, 46(3):488-491.
107. Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension 2009, 54(4):796-801.
108. Dahlberg J, Nilsson LO, von Wowern F, Melander O Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP. PLoS One 2007, 2(5):e432.
109. Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens 2011, 29(2):388-395.
110. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens 2013, 31(4):698-704.
111. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J 2013, 13(3):257-263.
112. Mason DA, Moore JD, Green SA, Liggett SB A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999, 274(18):12670-12674.
113. Johnson JA, Liggett SB Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 2011, 89(3):366-378.
114. Rathz DA, Brown KM, Kramer LA, Liggett SB Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002, 39(2):155-160.
115. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002, 277(34):30429-30435.
116. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003, 74(1):44-52.
117. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, et al. Beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006, 80(1):23-32.
118. Shin J, Johnson JA Pharmacogenetics of beta-blockers. Pharmacotherapy 2007, 27(6):874-887.
119. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000, 99(3):233-238.
120. Karlsson J, Lind L, Hallberg P, Michaëlsson K, Kurland L, Kahan T, et al. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004, 27(6):347-350.
121. Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension 2011, 57(5):903-910.
122. Bhatnagar V, O'Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, et al. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens 2009, 22(3):332-338.
123. Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, et al. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension 2012, 60(4):957-964.
124. Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J, Moss JI, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet 2009, 2(4):362-370.
125. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet 2010, 3(6):548-555.
126. Brenner R, Perez GJ, Bonev AD, Eckman DM, Kosek JC, Wiler SW, et al. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature 2000, 407(6806):870-876.
127. Pluger S, Faulhaber J, Furstenau M, Lohn M, Waldschutz R, Gollasch M, et al. Mice with disrupted BK channel beta1 subunit gene feature abnormal Ca(2+) spark/STOC coupling and elevated blood pressure. Circ Res 2000, 87(11):E53-E60.
128. Fernandez-Fernandez JM, Tomas M, Vazquez E, Orio P, Latorre R, Senti M, et al. Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J Clin Invest 2004, 113(7):1032-1039.
129. Senti M, Fernandez-Fernandez JM, Tomas M, Vazquez E, Elosua R, Marrugat J, et al. Protective effect of the KCNMB1 E65K genetic polymorphism against diastolic hypertension in aging women and its relevance to cardiovascular risk. Circ Res 2005, 97(12):1360-1365.
130. Gollasch M, Tank J, Luft FC, Jordan J, Maass P, Krasko C, et al. The BK channel beta1 subunit gene is associated with human baroreflex and blood pressure regulation. J Hypertens 2002, 20(5):927-933.
131. Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langaee TY, et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics 2007, 17(9):719-729.
132. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86(4):1343-1346.
133. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995, 39(2):131-134.
134. Nakano Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G, Kambe M Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997, 10(9 Pt 1):1064-1068.
135. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998, 11(2):174-183.
136. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003, 42(3):297-303.
137. Yu H, Zhang Y, Liu G Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res 2003, 26(11):881-886.
138. Redon J, Luque-Otero M, Martell N, Chaves FJ, Investigators P Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005, 5(1):14-20.
139. Nordestgaard BG, Kontula K, Benn M, Dahlof B, de Faire U, Edelman JM, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics 2010, 20(2):77-85.
140. Konoshita T, Kato N, Fuchs S, Mizuno S, Aoyama C, Motomura M, et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care 2009, 32(8):1485-1490.
141. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian study group of the effects of enalapril treatment in proteinuric renal disease. Kidney Blood Press Res 1998, 21(1):66-69.
142. O'Toole L, Stewart M, Padfield P, Channer K Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998, 32(6):988-994.
143. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000, 14(4):427-432.
144. Suwelack B, Kempkes-Koch M, Kobelt V, Hillebrand U, Matzkies F, Gerhardt U, et al. Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition. Transplant Proc 2002, 34(5):1763-1766.
145. Li X, Du Y, Huang X Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003, 8(1):25-30.
146. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71(1):169-180.
147. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995, 13(12 Pt 2):1602-1609.
148. Srivastava K, Chandra S, Bhatia J, Narang R, Saluja D Association of angiotensinogen (M235T) gene polymorphism with blood pressure lowering response to angiotensin converting enzyme inhibitor (Enalapril). J Pharm Pharm Sci 2012, 15(3):399-406.
149. Brunner M, Cooper-DeHoff RM, Gong Y, Karnes JH, Langaee TY, Pepine CJ, et al. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am J Cardiol 2007, 99(11):1549-1554.
150. Yu H, Lin S, Jin L, Yu Y, Zhong J, Zhang Y, et al. Adenine/cytosine(1166) polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J Hypertens 2009, 27(11):2278-2282.
151. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 2012, 59(6):1204-1211.
152. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003.
153. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008, 84(6):715-721.
154. Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, et al. Beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens 2008, 21(3):290-296.
155. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41(6):677-687.
156. Boczek NJ, Best JM, Tester DJ, Giudicessi JR, Middha S, Evans JM, et al. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long qt syndrome. Circ Cardiovasc Genet 2013, 6(3):279-289.
157. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294(14):1799-1809.
158. van 't Hooft FM, von Bahr SJ, Silveira A, Iliadou A, Eriksson P, Hamsten A Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol 1999, 19(12):3063-3070.
159. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995, 39(5):471-476.
160. Lynch AI, Boerwinkle E, Davis BR, et al. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics 2009, 19(6):415-421.
161. McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O, et al. Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension 2013, 62(1):48-54.
162. Yu Z, Lai CM, Maoui M, Banville D, Shen SH Identification and characterization of S2V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs. J Biol Chem 2001, 276(26):23816-23824.
163. Munday J, Floyd H, Crocker PR Sialic acid binding receptors (siglecs) expressed by macrophages. J Leukoc Biol 1999, 66(5):705-711.
164. Udby L, Sorensen OE, Pass J, Johnsen AH, Behrendt N, Borregaard N, et al. Cysteine-rich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma. Biochemistry 2004, 43(40):12877-12886.
165. Mann KG, Kalafatis M Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003, 101(1):20-30.
166. Kansas GS Selectins and their ligands: current concepts and controversies. Blood 1996, 88(9):3259-3287.
167. Auro K, Alanne M, Kristiansson K, Silander K, Kuulasmaa K, Salomaa V, et al. Combined effects of thrombosis pathway gene variants predict cardiovascular events. PLoS Genet 2007, 3(7):e120.
168. Barbaux SC, Blankenberg S, Rupprecht HJ, Francomme C, Bickel C, Hafner G, et al. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21(10):1668-1673.
169. Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet 1994, 3(11):1935-1937.
170. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002, 287(13):1680-1689.
171. Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the genetics of hypertension-associated treatment study. Pharmacogenomics J 2007, 7(2):112-122.
172. Gerhard T, Gong Y, Beitelshees AL, Mao X, Lobmeyer MT, Cooper-DeHoff RM, et al. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J 2008, 156(2):397-404.
173. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens 2009, 27(1):61-68.
174. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the genetics of hypertension-associated treatment (GenHAT) study. Circulation 2005, 111(25):3374-3383.
175. Schelleman H, Klungel OH, Witteman JC, Breteler MM, Hofman A, van Duijn CM, et al. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J 2008, 8(6):400-407.
176. Maitland-van der Zee AH, van Wieren-de Wijer DB, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. J Renin Angiotensin Aldosterone Syst 2011, 12(3):208-214.
177. Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, et al. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Pharmacogenet Genomics 2012, 22(5):355-366.
178. Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, et al. Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 2005, 115(7):1913-1922.
179. Price ET, Pacanowski MA, Martin MA, Cooper-DeHoff RM, Pepine CJ, Zineh I, et al. Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics 2011, 21(6):333-340.
180. Tanner RM, Lynch AI, Brophy VH, Eckfeldt JH, Davis BR, Ford CE, et al. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. PLoS One 2011, 6(8):e23609.
181. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003, 49(3):389-395.
182. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998, 32(3):521-526.
183. Colombo MG, Andreassi MG, Paradossi U, Botto N, Manfredi S, Masetti S, et al. Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298→Asp polymorphism) to the presence, extent, and severity of coronary artery disease. Heart 2002, 87(6):525-528.
184. Lenasi H, Kohlstedt K, Fichtlscherer B, Mulsch A, Busse R, Fleming I Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 2003, 59(4):844-853.
185. Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, et al. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS One 2012, 7(3):e34217.
186. Ackermann U Structure and function of atrial natriuretic peptides. Clin Chem 1986, 32(2):241-247.
187. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004, 35(4):814-818.
188. Dedoussis GV, Maumus S, Skoumas J, Choumerianou DM, Pitsavos C, Stefanadis C, et al. Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. J Clin Lab Anal 2006, 20(3):98-104.
189. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 2008, 299(3):296-307.
190. Kohler R, Brakemeier S, Kuhn M, Degenhardt C, Buhr H, Pries A, et al. Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res 2001, 51(1):160-168.
191. Shrestha S, Irvin MR, Taylor KD, Wiener HW, Pajewsk NM, Haritunians T, et al. A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS 2010, 24(4):583-592.
192. Yano M, Yamamoto T, Ikeda Y, Matsuzaki M Mechanisms of disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med 2006, 3(1):43-52.
193. Shibata MC, Leon H, Chatterley T, Dorgan M, Vandermeer B Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension?. Am J Cardiol 2010, 106(2):228-235.
194. Lynch AI, Irvin MR, Boerwinkle E, Davis BR, Vaughan LK, Ford CE, et al. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Pharmacogenomics J 2013, 13(4):330-334.
195. Schelleman H, Klungel OH, Witteman JC, Breteler MM, Yazdanpanah M, Danser AH, et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 2007, 15(4):478-484.
196. Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, et al. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Pharmacogenet Genomics 2012, 22(5):355-366.
197. Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet 2012, 5(6):686-691.
198. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008, 359(21):2208-2219.
199. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010, 376(9750):1393-1400.
200. Collins F Opportunities and challenges for the NIH-an interview with Francis Collins. Interview by Robert Steinbrook. N Engl J Med 2009, 361(14):1321-1323.
201. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al. The secondary prevention of small subcortical strokes (SPS3) study. Int J Stroke 2011, 6(2):164-175.
202. Padmanabhan S, Newton-Cheh C, Dominiczak AF Genetic basis of blood pressure and hypertension. Trends Genet 2012, 28(8):397-408.